While a group of cancer doctors were determined to find ways to reduce the treatment costs for Imbruvica, a blood cancer treatment, its maker tripled the price of the drug, according to a Washington Post report.
Imbruvica typically costs about $148,000 per year.
The scientists found evidence which suggested the treatment could work at one or two pills per day as opposed to the standard three-pills.
However, ahead of the research, Janssen and Pharmacyclics announced that the standard 140-milligram drug capsule would be canceled, and they would instead offer tablets in four strengths, all four of which bear the same price of roughly $400 — triple the original price.
“That got us kind of p—ed off,” University of Chicago Medicine Oncologist Dr. Mark Ratain said. “We were just in the early stages of planning (a clinical trial) and getting it organized, and thinking about sample size and funding, and we caught wind of what the company was doing.”